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LETTER TO THE EDITOR
Re: Intravenous versus Oral Busulfan—Perhaps Not
as Different as Suggested
The efﬁcacy, toxicity, and pharmacokinetics of
intravenous (IV) busulfan in a busulfan (BU)/cyclo-
phosphamide (CY) regimen were presented and dis-
cussed in a series of articles in BBMT [1-3]. Although
IV BU has a clear place in transplantation, there were
misleading omissions, assumptions, and conclusions in
some of the articles.
In the retrospective comparison of IV (0.8 mg/kg)
and oral (1 mg/kg) busulfan [1], Kashyap et al. [1]
concluded that IV busulfan is inherently safer than
oral delivery, in that the incidence of hepatic veno-
occlusive disease is lower and 100-day survival is
greater than with IV BU. Unfortunately, the compar-
ison failed to account for differences in busulfan area
under the plasma concentration–time curve (AUC).
An earlier publication by this group [3] reported AUC
data for IV busulfan, apparently in the same 61 pa-
tients in the later study [1]. The mean AUC in the 61
patients was 1167 M  min and the median was 1180
M  min. This result agrees well with the original
intent of the 0.8 mg/kg IV dose, which was selected to
yield an AUC of 1100-1200 M  min [4]. Oral busul-
fan at a dose of 1 mg/kg generally results in a mean
AUC of 1350-1400 M  min in adults (the distribu-
tion of clearance in adults is Gaussian) [5], an exposure
that borders on the lower limit of toxicity [6-8]. Be-
cause the dose–response relationship is steep, the 18%
higher AUC that was expected to be achieved with 1.0
mg/kg oral busulfan may well explain the apparently
lower incidence of toxicity. In contrast, the investiga-
tors speculate that the reason for the disparity in
outcome is a decrease in “hepatic ﬁrst-pass effect”
afforded by the IV route of administration.
The authors most likely used the term “ﬁrst-pass
effect” to refer to presumed high plasma concentra-
tions during the period of busulfan absorption from
the gut. A simple calculation suggests that hepatic
plasma concentration should not be expected to be
particularly high relative to concentrations observed
in the peripheral circulation. Hepatic blood ﬂow is
about 1.5 L/min in a 70-kg person; because busulfan
freely distributes into erythrocytes, plasma and blood
concentrations are equal. If such a person received 1
mg/kg of busulfan and it was absorbed over 90 min-
utes it would produce a concentration of 520 ng/mL
in the 135 L of blood into which it entered. Busulfan
is not quickly absorbed; peak concentrations following
administration of tablets are typically about 60-90 min
after administration because the peak is observed at
the point that the rate of absorption equals the rate of
elimination. This should be compared to the median
peak plasma concentration following IV administra-
tion of 0.8 mg/kg of about 940 ng/mL following the
ﬁrst dose and 1222 ng/mL after dose 9 in the patients
studied by Kashyap et al. [1] according to the report
by Andersson et al. [3]. Of course, this simple calcu-
lation ignores the fact that busulfan may be present in
blood approaching the site of absorption, just as it
ignores that the absorption rate is highest when there
is no busulfan in that blood (as absorption ﬁrst starts)
and that the rate of absorption slows as drug vanishes
from the lumen of the intestine.
The relatively small difference in oral versus in-
travenous peak concentration experienced by the liver
can be illustrated more quantitatively by a different
approach that relies on principles of mass balance and
clearance. This approach also allows a consideration
of the toxicologically more relevant variable, AUC.
Regardless of what the peak concentration actually is,
veno-occlusive disease of the liver has not been related
to peak concentration, but to AUC. That peak con-
centration may not be critical (at least in the range
encountered clinically) is reinforced by the lack of an
increase in toxicity when the drug is administered
once or twice daily, as is being studied at several
centers. For example, once daily 3.2 mg/kg IV infu-
sion of busulfan over 3 hours [9] achieves a maximum
busulfan plasma concentration about 3 times higher
than observed after a 2-hour infusion of 0.8 mg/kg,
apparently without enhanced toxicity (although used
with ﬂudarabine rather than cyclophosphamide). In an
editorial accompanying the Kashyap et al. paper [1],
Grochow [10] argued that an increase in busulfan peak
concentration of 3 times would not be toxicologically
signiﬁcant. The difference between the AUC that the
liver actually sees following a given dose orally versus
the AUC after an IV dose can easily be appreciated
from the clearance data presented by Andersson et al.
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[3]. From these data, a maximum hepatic extraction
ratio (the ratio of clearance to hepatic blood ﬂow) of
approximately 12% can be calculated (this number is a
maximum estimate because busulfan is eliminated in
the enterocytes and other nonhepatic sites) [11]. From
fundamental pharmacokinetic principles of mass bal-
ance, this means that the AUC of busulfan in the
blood of the portal vein is (maximally) 12% higher
than that of the peripheral circulation from which
blood samples are taken. Once absorption is complete
(peak plasma levels are observed at about 1 hour with
the oral formulation), the concentration of busulfan in
the blood entering the liver must be equal to that in
the peripheral circulation at the same instant. Given
these two considerations, it is impossible that the
highest blood concentration entering the liver from
the splanchnic circulation after either oral or IV ad-
ministration of busulfan will signiﬁcantly exceed (in
the toxicological sense) the peak plasma concentration
observed in the periphery. During the period of busul-
fan absorption, on average, portal blood concentration
will modestly exceed that concentration noted periph-
erally, resulting in the (maximally) 12% higher portal
blood busulfan AUC.
It is possible that there is some toxicologic rele-
vance, as it follows from this argument that to achieve
a given AUC peripherally the liver must experience a
(maximally) 12% higher AUC after oral administra-
tion than after IV administration. However, the pe-
ripheral blood busulfan AUC difference in the retro-
spective comparison of IV to oral busulfan reported by
Kashyap et al. [1] is expected to be 18%, based on the
different IV and oral doses administered. A fair eval-
uation of outcome of IV versus oral administration
must await an AUC-matched phase III comparison.
Another paper in this series [12] reports that
1-year survival following allogeneic transplantation
for CML using the same BU/CY regimen is compro-
mised by busulfan AUC below 950 or above 1500
M  min. Four of 8 patients with AUC  1500 M 
min died of chronic graft versus host disease (GVHD),
a cause of death not previously attributed to busulfan.
Twelve of 36 patients in the study experienced acute
GVHD. The authors concluded that “precise Bu de-
livery may be even more important than previously
thought, not only in relation to regimen-related tox-
icity, but also in the development of clinically signif-
icant acute GVHD and for the likelihood of being
alive beyond 1 year after hematopoietic stem cell
transplantation.” Substantially more study is needed
before such a conclusion is warranted. We have pre-
viously reported that patients with chronic myeloge-
nous leukemia receiving HLA-matched sibling grafts
tolerate busulfan AUC above 1375 M  min well (in
a BU/CY 120 mg/kg regimen), experiencing no in-
creased incidence of regimen-related toxicity and a
substantially lower level of relapse [12]. These results
recently have been extended. In 131 patients targeted
to BU AUC  1350 M  min, the probabilities of
nonrelapse mortality, relapse, survival, and disease-
free survival 3 years after transplantation were 14%,
8%, 86% and 78%, respectively [13]. Of these patients
46 had busulfan AUC  1500 M  min.
Because the busulfan pharmacokinetic laboratory
of the Seattle Cancer Care Alliance receives samples
from roughly 60 centers for busulfan targeting, we
have had ample opportunity to observe the pharma-
cokinetic behavior of the IV formulation. The inter-
patient coefﬁcient variation of clearance (AUC at a
given dose) is comparable between the two routes of
administration in adults, whereas the IV formulation
offers a distinct advantage in diminishing dose-to-
dose variability over the oral route. Supporting IV
data have been published in the Busulfex (Orphan
Medical Inc, Minnetonka, MN) product labeling [3],
and oral data have been summarized from several
studies [14]. Gibbs et al. [15] report a large oral series.
This advantage is important when sending samples to
a remote site for the purpose of targeting AUC (or
average steady-state concentration). Intravenous ad-
ministration appears to offer an additional advantage
in infants and young children, in whom interpatient
busulfan AUC following oral administration is more
variable than in adults [13]. However, on the basis of
published evidence, it should not be concluded that
the IV formulation offers a toxicologic advantage
when comparable peripheral AUCs are obtained, nor
should it be concluded that IV busulfan increases the
incidence of GVHD. Further, the bulk of the available
evidence suggests that CML patients receiving busul-
fan AUC of 1350 M  min are at risk of relapse.
This risk is substantially greater than the risk of excess
toxicity following AUC  1500 M  min.
John T. Slattery, PhD
Fred Hutchinson Cancer Research Center
Seattle, WA
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